Bayer and Loxo Oncology to develop new cancer therapies

Bayer has announced a new collaboration with Loxo Oncology, which will focus on the development of two novel therapies selectively targeting genetic drivers of cancer.

The partnership will centre on the development and commercialisation of larotrectinib and LOXO-195, two compounds that are being investigated in global studies for the treatment of patients with cancers harbouring tropomyosin receptor kinase (TRK) gene fusions.

These genetic alterations are seen in a wide range of tumour types and can result in uncontrolled TRK signalling and tumour growth, meaning they are seen as a promising target for new therapies.

Larotrectinib is currently the only selective TRK inhibitor in clinical development, with data accumulated so far showing clinically meaningful and durable responses, and an overall response rate of 75 percent. 

The first filing for larotrectinib is planned in the US in late 2017 or early 2018, with the EU filing to follow later in 2018. 

Dieter Weinand, member of the Bayer board of management and president of its pharmaceuticals division, said: "The collaboration with Loxo Oncology represents another milestone in our endeavor to strengthen our oncology presence and underlines our commitment to this therapeutic area."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.